Kidney Disease Clinical Trial
Official title:
Kidney Disease Biomarkers
Verified date | December 3, 2014 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Kidney Disease Biomarkers
Summary: This study will identify biomarkers (proteins and other molecules in the blood or
urine) that may help scientists predict what kidney disease a patient has and whether a given
patient would respond to particular therapies. The study will look for biomarkers in the
blood and urine of patients with various kidney diseases and study of the effects of
angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers
(ARB) on biomarkers. Blood and urine from healthy volunteers will be studied for comparison.
Healthy people and the following patients may be eligible for this study: adults with
diabetic nephropathy 18 years of age and older; children with newly diagnosed clinical
idiopathic nephrotic syndrome between 2 and 18 year of age; children and adults with
glomerular disease (minimal change disease, focal segmental glomerulosclerosis, or collapsing
glomerulopathy).
Participants undergo tests and procedures as follows:
Glomerular Disease: Adults with glomerular disease provide about four to six blood and urine
samples over the course of 6 to 12 months. The samples are collected at the time of regularly
scheduled visits for the NIH treatment protocol in which they are participating. Children
provide only blood samples.
Chronic Kidney Disease: Patients with chronic kidney disease provide a blood and urine sample
every 6 months for 3 years or more.
Angiotensin Antagonism: Patients with chronic kidney disease who are taking ACE inhibitors or
ARBs stop their medicines for 4 weeks, while those who are not taking ACE inhibitors or ARBs
begin one of the medicines. In general, patients just starting on the medications continue
them after the study is completed, since they are beneficial for chronic kidney disease.
- Medication withdrawal group: Patients come to NIH for 2 successive days at the beginning
of the study for blood and urine tests (including one 24-hour urine collection) and to
receive iothalamate (a chemical used to measure kidney function). Iothalamate is
delivered over 24 hours through a needle placed in the abdomen (or elsewhere) via a pump
similar to pumps that some diabetics use to deliver insulin. Patients then stop taking
their ACE inhibitor or ARB medication. They monitor their blood pressure every day and
return to NIH after 1, 2 and 4 weeks for blood tests. During week 4, the iothalamate
infusion is repeated, and blood and urine samples are collected as at the beginning of
the study. Patients then resume taking their ACE inhibitor or ARB once a day with the
dose being increased at 2-week intervals. They come to NIH weekly after 1 week and then
every other week for blood tests. Four weeks after reaching the highest FDA-recommended
dose of medication tolerated, the iothalamate infusion and blood and urine collections
are repeated.
- Medication induction group: At the beginning of the study, patients have the iothalamate
infusion and blood and urine collections described above and then begin to take either
an ACE inhibitor or ARB. The dose is increased after 2 weeks. Patients monitor their
blood pressure every day. After being on the highest dose for 4 weeks, patients repeat
the iothalamate infusion and blood and urine collections. The study is then complete and
they are provided a 2-month supply of medicine to take home.
Information is gathered on symptoms, treatments, and results of past laboratory tests of all
patients. Healthy volunteers provide blood and urine sample collections every month or every
other month for up to four collections to be used for biomarker studies and the screen for
common chronic diseases.
Status | Completed |
Enrollment | 25 |
Est. completion date | December 3, 2014 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility |
- INCLUSION CRITERIA: 1. Children with newly diagnosed clinical idiopathic nephrotic syndrome between the ages of 2-18 years. 2. Children with previously diagnosed clinical idiopathic nephrotic syndrome between the age of 2-18 years at the time of diagnosis who sustain a relapse of nephrotic syndrome while off steroid therapy. A relapse is defined as a urine protein level of 2+ (100mg/dl) or greater on a first morning urine sample for 3 consecutive days. While a quantitative urine protein/creatinine ratio is more precise, this semi-quantitative definition accords with pediatric practice. Relapses will be treated according to standard clinical practice. 3. Children and adults who participate in NIH trials of remittive therapy for MCD/FSGS/CG (e.g. Podocyte dexamethasone or Retinoids for podocyte disease) will be eligible. 4. Also, we will study up to 10 healthy adult volunteers. EXCLUSION CRITERIA: 1. IN CHILDREN, ANY OF THE FOLLOWING 1. Age less than 2 years. The rationale for excluding children under the age of 2 yr is that nephrotic syndrome is unusual in this age group and may have etiologies other than MCD and FSGS 2. Uncontrolled hypertension (a systolic or diastolic which is greater than 95% population mean for child s age and sex, while receiving therapy), azotemia (serum creatinine greater than 1.5mg/dL), gross hematuria at the time of presentation (clinical markers of primary or secondary GN). 3. Hypocomplementemia, positive ANA, anti-DS DNA, ASO, anti-DNase B, MPO, PR-3, Hepatitis B and C and HIV serologies. 2. In children or adults: 1. Clinical contra-indications to steroid therapy. 2. The presence of medical conditions that might interfere with the interpretation of results, such as cancer, diabetes, or a long history of hypertension. 3. Healthy adult volunteers: 1. age greater than 18 yrs; no history of hypertension, diabetes, or other chronic illness that might complicate interpretation of the results; not taking prescription medication. CKD PROGRESSION STUDY: INCLUSION CRITERIA: 1. Renal biopsy diagnosis of glomerular disease or interstitial nephritis or clinical diagnosis of diabetic nephropathy. 2. Mild or moderate renal insufficiency, defined as eGFR less than 60 ml/min/1.73m(2) but greater than 30 ml/min/1.73m(2). EXCLUSION CRITERIA: 1) The presence of medical conditions that might interfere with the interpretation of results, such as cancer. ANGIOTENSIN ANTAGONISM STUDY: INCLUSION CRITERIA: 1. Adults greater than 18 years old. Few children have diabetic nephropathy and the frequent blood draws would be problematic for children. 2. Type 1 or Type 2 diabetes. Later studies will be expanded to other glomerular diseases. 3. Urinary albumin/creatinine ratio greater than 30 mg/g. The rationale is to include patients with macroproteinuria and patients with microalbuminuria. 4. Estimated GFR greater than 30 mL/min/1.73m(2). The rationale is to exclude patients with severe CKD. EXCLUSION CRITERIA: 1. Allergy to ACE inhibitor or ARB 2. Current or planned pregnancy; urine HCG performed at start of study and on the day of iothalamate infusion. 3. Serum potassium greater than 5.0 mEq/L off angiotensin antagonist therapy 4. The presence of medical conditions which would make interpretation of results difficult such as cancer. 5. History of iodine allergy or severe asthma (history of emergency department visit or hospitalization). SEX DIFFERENCES IN URINARY EXOSOME PROTEINS: INCLUSION CRITERIA: 1. Age 18-30; Young adults are less likely to have undetected chronic renal disease. 2. BMI 18-27.5 kg/m(2); Obesity may alter renal function. 3. BP consistently less than 130/80; Pre-hypertension or hypertension may affect the kidney. EXCLUSION CRITERIA: 1. Any chronic illness that might interfere with interpretation of the study; certain illnesses that do not require therapy may be consistent with inclusion, including mild asthma or psychiatric illness. 2. Cancer other than non-melanoma skin cancer in the past 5 years. 3. Need for any chronic or intermittent medication other than acetaminophen. 4. Women: amenorrhea, irregular menses, menstrual cycles less than 26 days or greater than 32 days, or use of contraceptive hormones (unwilling or unable to switch to non-hormonal means of contraception); Irregular cycle may be non-ovulatory and associated with abnormal sex hormone profiles, which will complicate data interpretation. 5. Use of nicotine or illicit drugs. 6. Febrile illness or urinary tract infection: postpone admission one week or more. SALT INTAKE AND BLOOD PRESSURE RESPONSES IN URINARY EXOSOMES: INCLUSION CRITERIA: 1. Men Age 18-35 2. BMI 18-25 kg/m(2) 3. BP consistently less than 130/80 EXCLUSION CRITERIA: 1. Any chronic illness that might interfere with interpretation of the study; certain illnesses that do not require therapy may be consistent with inclusion, including mild asthma or psychiatric illness 2. Cancer other than non-melanoma skin cancer in the past 5 years 3. Need for any chronic or intermittent medication other than acetaminophen 4. Use of nicotine or illicit drug 5. Febrile illness or urinary tract infection: postpone admission one week or more |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Barisoni L, Kopp JB. Modulation of podocyte phenotype in collapsing glomerulopathies. Microsc Res Tech. 2002 May 15;57(4):254-62. — View Citation
Hortin GL, Meilinger B, Drake SK. Size-selective extraction of peptides from urine for mass spectrometric analysis. Clin Chem. 2004 Jun;50(6):1092-5. — View Citation
Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol. 2003 Mar;23(2):147-60. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02369354 -
Transplant Social Worker Support for Live Kidney Donation in African Americans
|
N/A | |
Not yet recruiting |
NCT02225782 -
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
|
Phase 4 | |
Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
Terminated |
NCT00436748 -
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
Completed |
NCT01235936 -
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
|
Phase 2 | |
Completed |
NCT01947829 -
Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)
|
N/A | |
Completed |
NCT01974999 -
A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study
|
||
Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
Active, not recruiting |
NCT01228903 -
Uric Acid and the Endothelium is CKD
|
N/A | |
Completed |
NCT00734357 -
Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients
|
N/A | |
Completed |
NCT00781417 -
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
|
N/A | |
Completed |
NCT00096915 -
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
|
Phase 3 | |
Completed |
NCT00093977 -
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT00185159 -
Olmesartan Medoxomil in Diabetes Mellitus
|
Phase 3 |